1. Smith TJ, Hegedus L. Graves' disease. N Engl J Med 2016;375:1552-1565.
[CROSSREF]
2. Nystrom HF, Jansson S, Berg G. Incidence rate and clinical features of hyperthyroidism in a long-term iodine sufficient area of Sweden (Gothenburg) 2003-2005. Clin Endocrinol (Oxf) 2013;78:768-776.
[CROSSREF]
3. Hussain YS, Hookham JC, Allahabadia A, Balasubramanian SP. Epidemiology, management and outcomes of Graves' disease-real life data. Endocrine 2017;56:568-578.
[CROSSREF] [PUBMED] [PMC] [PDF]
4. Wass JAH, Stewart PM. Chapter 3.3.6, Antithyroid drug treatment for thyrotoxicosis. Oxford textbook of endocrinology and diabetes. 2nd ed. Oxford: Oxford University Pres; 2011. p. 476-480.
5. Ross DS, Burch HB, Cooper DS, Greenlee MC, Laurberg P, Maia AL, et al. 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid 2016;26:1343-1421.
[CROSSREF] [PUBMED]
6. Kahaly GJ, Bartalena L, Hegedus L, Leenhardt L, Poppe K, Pearce SH. 2018 European Thyroid Association guideline for the management of Graves' hyperthyroidism. Eur Thyroid J 2018;7:167-186.
[CROSSREF] [PUBMED] [PMC]
7. Guo Z, Yu P, Liu Z, Si Y, Jin M. Total thyroidectomy vs bilateral subtotal thyroidectomy in patients with Graves' diseases: a meta-analysis of randomized clinical trials. Clin Endocrinol (Oxf) 2013;79:739-746.
[PUBMED]
8. Genovese BM, Noureldine SI, Gleeson EM, Tufano RP, Kandil E. What is the best definitive treatment for Graves' disease? A systematic review of the existing literature. Ann Surg Oncol 2013;20:660-667.
[CROSSREF] [PUBMED] [PDF]
9. Liu ZW, Masterson L, Fish B, Jani P, Chatterjee K. Thyroid surgery for Graves' disease and Graves' ophthalmopathy. Cochrane Database Syst Rev 2015;(11):CD010576.
[CROSSREF]
10. Kautbally S, Alexopoulou O, Daumerie C, Jamar F, Mourad M, Maiter D. Greater efficacy of total thyroidectomy versus radioiodine therapy on hyperthyroidism and thyroid-stimulating immunoglobulin levels in patients with Graves' disease previously treated with antithyroid drugs. Eur Thyroid J 2012;1:122-128.
[CROSSREF] [PUBMED] [PMC]
11. Lin YS, Lin JD, Hsu CC, Yu MC. The long-term outcomes of thyroid function after subtotal thyroidectomy for Graves' hyperthyroidism. J Surg Res 2017;220:112-118.
[CROSSREF] [PUBMED]
12. Huang CS, Wang M, Shun CT, Liaw KY. Factors affecting thyroid function after thyroidectomy for Graves' disease. J Formos Med Assoc 1995;94:423-427.
[PUBMED]
13. Aung ET, Zammitt NN, Dover AR, Strachan MWJ, Seckl JR, Gibb FW. Predicting outcomes and complications following radioiodine therapy in Graves' thyrotoxicosis. Clin Endocrinol (Oxf) 2019;90:192-199.
[CROSSREF] [PUBMED]
14. Laurberg P, Wallin G, Tallstedt L, Abraham-Nordling M, Lundell G, Torring O. TSH-receptor autoimmunity in Graves' disease after therapy with anti-thyroid drugs, surgery, or radioiodine: a 5-year prospective randomized study. Eur J Endocrinol 2008;158:69-75.
[CROSSREF]
15. Ma C, Xie J, Wang H, Li J, Chen S. Radioiodine therapy versus antithyroid medications for Graves’ disease. Cochrane Database Syst Rev 2016;2:CD010094.
[CROSSREF] [PUBMED]
16. Fanning E, Inder WJ, Mackenzie E. Radioiodine treatment for Graves' disease: a 10-year Australian cohort study. BMC Endocr Disord 2018;18:94
[CROSSREF] [PDF]
17. Hyer SL, Pratt B, Gray M, Chittenden S, Du Y, Harmer CL, et al. Dosimetry-based treatment for Graves' disease. Nucl Med Commun 2018;39:486-492.
[CROSSREF] [PUBMED] [PMC]
18. Chen DY, Schneider PF, Zhang XS, He ZM, Jing J, Chen TH. Striving for euthyroidism in radioiodine therapy of Graves' disease: a 12-year prospective, randomized, open-label blinded end point study. Thyroid 2011;21:647-654.
[CROSSREF] [PUBMED]
19. Burch HB, Burman KD, Cooper DS. A 2011 survey of clinical practice patterns in the management of Graves' disease. J Clin Endocrinol Metab 2012;97:4549-4558.
[CROSSREF] [PDF]
20. Brito JP, Schilz S, Singh Ospina N, Rodriguez-Gutierrez R, Maraka S, Sangaralingham LR, et al. Antithyroid drugs-the most common treatment for Graves' disease in the United States: a nationwide population-based study. Thyroid 2016;26:1144-1145.
[CROSSREF] [PUBMED]
21. Burch HB, Cooper DS. Anniversary review: antithyroid drug therapy: 70 years later. Eur J Endocrinol 2018;179:R261-R274.
[CROSSREF] [PUBMED]
22. Struja T, Fehlberg H, Kutz A, Guebelin L, Degen C, Mueller B, et al. Can we predict relapse in Graves' disease? Results from a systematic review and meta-analysis. Eur J Endocrinol 2017;176:87-97.
[CROSSREF] [PUBMED]
23. Vos XG, Endert E, Zwinderman AH, Tijssen JG, Wiersinga WM. Predicting the risk of recurrence before the start of antithyroid drug therapy in patients with Graves’ hyperthyroidism. J Clin Endocrinol Metab 2016;101:1381-1389.
[CROSSREF] [PUBMED]
24. Struja T, Kaeslin M, Boesiger F, Jutzi R, Imahorn N, Kutz A, et al. External validation of the GREAT score to predict relapse risk in Graves' disease: results from a multicenter, retrospective study with 741 patients. Eur J Endocrinol 2017;176:413-419.
[CROSSREF] [PUBMED]
25. Masiello E, Veronesi G, Gallo D, Premoli P, Bianconi E, Rosetti S, et al. Antithyroid drug treatment for Graves' disease: baseline predictive models of relapse after treatment for a patient-tailored management. J Endocrinol Invest 2018;41:1425-1432.
[CROSSREF] [PUBMED] [PDF]
26. Giuliani C, Cerrone D, Harii N, Thornton M, Kohn LD, Dagia NM, et al. A TSHR-LH/CGR chimera that measures functional thyroid-stimulating autoantibodies (TSAb) can predict remission or recurrence in Graves' patients undergoing antithyroid drug (ATD) treatment. J Clin Endocrinol Metab 2012;97:E1080-E1087.
[CROSSREF] [PUBMED]
27. Kwon H, Kim WG, Jang EK, Kim M, Park S, Jeon MJ, et al. Usefulness of measuring thyroid stimulating antibody at the time of antithyroid drug withdrawal for predicting relapse of Graves disease. Endocrinol Metab (Seoul) 2016;31:300-310.
[CROSSREF] [PUBMED] [PMC]
28. Eliana F, Suwondo P, Asmarinah A, Harahap A, Djauzi S, Prihartono J, et al. The role of cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) gene, thyroid stimulating hormone receptor (TSHR) gene and regulatory t-cells as risk factors for relapse in patients with Graves disease. Acta Med Indones 2017;49:195-204.
[PUBMED]
29. Garcia-Mayor RV, Alvarez-Vazquez P, Fluiters E, Valverde D, Andrade A. Long-term remission following antithyroid drug withdrawal in patients with Graves' hyperthyroidism: parameters with prognostic value. Endocrine 2019;63:316-322.
[CROSSREF] [PUBMED] [PDF]
30. Mohlin E, Filipsson Nystrom H, Eliasson M. Long-term prognosis after medical treatment of Graves' disease in a northern Swedish population 2000-2010. Eur J Endocrinol 2014;170:419-427.
[CROSSREF] [PUBMED]
31. Abraham P, Avenell A, Park CM, Watson WA, Bevan JS. A systematic review of drug therapy for Graves' hyperthyroidism. Eur J Endocrinol 2005;153:489-498.
[CROSSREF]
32. Razvi S, Vaidya B, Perros P, Pearce SH. What is the evidence behind the evidence-base? The premature death of block-replace antithyroid drug regimens for Graves' disease. Eur J Endocrinol 2006;154:783-786.
[CROSSREF] [PUBMED]
33. Park SM, Cho YY, Joung JY, Sohn SY, Kim SW, Chung JH. Excessive iodine intake does not increase the recurrence rate of Graves' disease after withdrawal of the antithyroid drug in an iodine-replete area. Eur Thyroid J 2015;4:36-42.
[CROSSREF] [PUBMED] [PMC]
34. Volpe R. The immunomodulatory effects of anti-thyroid drugs are mediated via actions on thyroid cells, affecting thyrocyte-immunocyte signalling: a review. Curr Pharm Des 2001;7:451-460.
[CROSSREF] [PUBMED]
35. Laurberg P. Remission of Graves’ disease during anti-thyroid drug therapy. Time to reconsider the mechanism? Eur J Endocrinol 2006;155:783-786.
[CROSSREF] [PUBMED]
36. Hashizume K, Ichikawa K, Sakurai A, Suzuki S, Takeda T, Kobayashi M, et al. Administration of thyroxine in treated Graves' disease. Effects on the level of antibodies to thyroid-stimulating hormone receptors and on the risk of recurrence of hyperthyroidism. N Engl J Med 1991;324:947-953.
[CROSSREF] [PUBMED]
37. Tamai H, Hayaki I, Kawai K, Komaki G, Matsubayashi S, Kuma K, et al. Lack of effect of thyroxine administration on elevated thyroid stimulating hormone receptor antibody levels in treated Graves' disease patients. J Clin Endocrinol Metab 1995;80:1481-1484.
[PUBMED]
38. Mori T, Sugawa H, Kosugi S, Ueda M, Hai N, Matsuda A. Recent trends in the management of Graves' hyperthyroidism in Japan: opinion survey results, especially on the combination therapy of antithyroid drug and thyroid hormone. Endocr J 1997;44:509-517.
[CROSSREF] [PUBMED]
39. Wang L, Wang B, Chen SR, Hou X, Wang XF, Zhao SH, et al. Effect of selenium supplementation on recurrent hyperthyroidism caused by Graves' disease: a prospective pilot study. Horm Metab Res 2016;48:559-564.
[CROSSREF] [PUBMED] [PDF]
40. Kahaly GJ, Riedl M, Konig J, Diana T, Schomburg L. Double-blind, placebo-controlled, randomized trial of selenium in Graves hyperthyroidism. J Clin Endocrinol Metab 2017;102:4333-4341.
[CROSSREF] [PDF]
41. Liu X, Qiang W, Liu X, Liu L, Liu S, Gao A, et al. A second course of antithyroid drug therapy for recurrent Graves' disease: an experience in endocrine practice. Eur J Endocrinol 2015;172:321-326.
[CROSSREF] [PUBMED] [PMC]
42. Kim YA, Cho SW, Choi HS, Moon S, Moon JH, Kim KW, et al. The second antithyroid drug treatment is effective in relapsed Graves' disease patients: a median 11-year follow-up study. Thyroid 2017;27:491-496.
[CROSSREF] [PUBMED]
43. Elbers L, Mourits M, Wiersinga W. Outcome of very long-term treatment with antithyroid drugs in Graves' hyperthyroidism associated with Graves' orbitopathy. Thyroid 2011;21:279-283.
[CROSSREF] [PUBMED]
44. Laurberg P, Berman DC, Andersen S, Bulow Pedersen I. Sustained control of Graves' hyperthyroidism during long-term low-dose antithyroid drug therapy of patients with severe Graves' orbitopathy. Thyroid 2011;21:951-956.
[CROSSREF] [PUBMED]
45. Azizi F, Malboosbaf R. Long-term antithyroid drug treatment: a systematic review and meta-analysis. Thyroid 2017;27:1223-1231.
[CROSSREF] [PUBMED]
46. Azizi F, Ataie L, Hedayati M, Mehrabi Y, Sheikholeslami F. Effect of long-term continuous methimazole treatment of hyperthyroidism: comparison with radioiodine. Eur J Endocrinol 2005;152:695-701.
[CROSSREF] [PUBMED]
47. Villagelin D, Romaldini JH, Santos RB, Milkos AB, Ward LS. Outcomes in relapsed Graves' disease patients following radioiodine or prolonged low dose of methimazole treatment. Thyroid 2015;25:1282-1290.
[CROSSREF] [PUBMED]
48. Irvine WJ, Gray RS, Toft AD, Seth J, Lidgard GP, Cameron EH. Spectrum of thyroid function in patient's remaining in remission after antithyroid drug therapy for thyrotoxicosis. Lancet 1977;2:179-181.
[CROSSREF] [PUBMED]
49. Wood LC, Ingbar SH. Hypothyroidism as a late sequela in patient with Graves’ disease treated with antithyroid agents. J Clin Invest 1979;64:1429-1436.
[CROSSREF] [PUBMED] [PMC]
50. Hirota Y, Tamai H, Hayashi Y, Matsubayashi S, Matsuzuka F, Kuma K, et al. Thyroid function and histology in forty-five patients with hyperthyroid Graves' disease in clinical remission more than ten years after thionamide drug treatment. J Clin Endocrinol Metab 1986;62:165-169.
[CROSSREF] [PUBMED] [PDF]
51. Tamai H, Kasagi K, Takaichi Y, Takamatsu J, Komaki G, Matsubayashi S, et al. Development of spontaneous hypothyroidism in patients with Graves' disease treated with antithyroidal drugs: clinical, immunological, and histological findings in 26 patients. J Clin Endocrinol Metab 1989;69:49-53.
[CROSSREF] [PUBMED] [PDF]
52. Strieder TG, Tijssen JG, Wenzel BE, Endert E, Wiersinga WM. Prediction of progression to overt hypothyroidism or hyperthyroidism in female relatives of patients with autoimmune thyroid disease using the Thyroid Events Amsterdam (THEA) score. Arch Intern Med 2008;168:1657-1663.
[CROSSREF] [PUBMED]
53. Takaichi Y, Tamai H, Honda K, Nagai K, Kuma K, Nakagawa T. The significance of antithyroglobulin and antithyroidal microsomal antibodies in patients with hyperthyroidism due to Graves' disease treated with antithyroidal drugs. J Clin Endocrinol Metab 1989;68:1097-1100.
[CROSSREF] [PUBMED] [PDF]
54. Stefanic M, Karner I. Thyroid peroxidase autoantibodies are associated with a lesser likelihood of late reversion to hyperthyroidism after successful non-ablative treatment of Graves' disease in Croatian patients. J Endocrinol Invest 2014;37:71-77.
[CROSSREF] [PUBMED] [PDF]
55. Lin HD, Tai FT, Chen HD, Lee SP, Chang FY, Wang GG, et al. Change of circulating thyroid autoantibody titers in Graves' hyperthyroidism after antithyroid drugs therapy. Zhonghua Yi Xue Za Zhi (Taipei) 1991;47:86-90.
[PUBMED]
56. Schott M, Eckstein A, Willenberg HS, Nguyen TB, Morgenthaler NG, Scherbaum WA. Improved prediction of relapse of Graves' thyrotoxicosis by combined determination of TSH receptor and thyroperoxidase antibodies. Horm Metab Res 2007;39:56-61.
[CROSSREF] [PUBMED] [PDF]
57. Gill RG, Harmon JT, McLaren NK. Chapter 18, Autoimmune thyroid diseases. Immunologically mediated endocrine diseases. Philadelphia: Lippincott Williams & Wilkins; 2002. p. 373-396.
58. Wong M, Inder WJ. Alternating hyperthyroidism and hypothyroidism in Graves' disease. Clin Case Rep 2018;6:1684-1688.
[CROSSREF] [PUBMED] [PMC]